- Category: Approved HCV Drugs
- Published on Tuesday, 09 December 2014 00:00
- Written by Liz Highleyman
Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of therapy with first-generation HCV protease inhibitors had a sustained virological response rate of 97% when retreated with sofosbuvir/ledipasvir (Harvoni) for 24 weeks, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Sofosbuvir/ledipasvir also worked worked well for people previously treated with other sofosbuvir-containing regimens.